TY - JOUR
T1 - Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs
AU - Mercurio, Valentina
AU - Pirozzi, Flora
AU - Lazzarini, Edoardo
AU - Marone, Giancarlo
AU - Rizzo, Paola
AU - Agnetti, Giulio
AU - Tocchetti, Carlo G.
AU - Ghigo, Alessandra
AU - Ameri, Pietro
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Heart failure (HF) is a complication of oncological treatments that may have dramatic clinical impact. It may acutely worsen a patient's condition or it may present with delayed onset, even years after treatment, when cancer has been cured or is in stable remission. Several studies have addressed the mechanisms of cancer therapy-related HF and some have led to the definition of disease models that hold valid for other and more common types of HF. Here, we review these models of HF based on the cardiotoxicity of antineoplastic drugs and classify them in cardiomyocyte-intrinsic, paracrine, or potentially secondary to effects on cardiac progenitor cells. The first group includes HF resulting from the combination of oxidative stress, mitochondrial dysfunction, and activation of the DNA damage response, which is typically caused by anthracyclines, and HF resulting from deranged myocardial energetics, such as that triggered by anthracyclines and sunitinib. Blockade of the neuregulin-1/ErbB4/ErbB2, vascular endothelial growth factor/vascular endothelial growth factor receptor and platelet-derived growth factor /platelet-derived growth factor receptor pathways by trastuzumab, sorafenib and sunitinib is proposed as paradigm of cancer therapy-related HF associated with alterations of myocardial paracrine pathways. Finally, anthracyclines and trastuzumab are also presented as examples of antitumor agents that induce HF by affecting the cardiac progenitor cell population.
AB - Heart failure (HF) is a complication of oncological treatments that may have dramatic clinical impact. It may acutely worsen a patient's condition or it may present with delayed onset, even years after treatment, when cancer has been cured or is in stable remission. Several studies have addressed the mechanisms of cancer therapy-related HF and some have led to the definition of disease models that hold valid for other and more common types of HF. Here, we review these models of HF based on the cardiotoxicity of antineoplastic drugs and classify them in cardiomyocyte-intrinsic, paracrine, or potentially secondary to effects on cardiac progenitor cells. The first group includes HF resulting from the combination of oxidative stress, mitochondrial dysfunction, and activation of the DNA damage response, which is typically caused by anthracyclines, and HF resulting from deranged myocardial energetics, such as that triggered by anthracyclines and sunitinib. Blockade of the neuregulin-1/ErbB4/ErbB2, vascular endothelial growth factor/vascular endothelial growth factor receptor and platelet-derived growth factor /platelet-derived growth factor receptor pathways by trastuzumab, sorafenib and sunitinib is proposed as paradigm of cancer therapy-related HF associated with alterations of myocardial paracrine pathways. Finally, anthracyclines and trastuzumab are also presented as examples of antitumor agents that induce HF by affecting the cardiac progenitor cell population.
KW - Heart failure
KW - anthracyclines
KW - antineoplastic drugs-induced cardiotoxicity
KW - receptor tyrosine kinase
UR - http://www.scopus.com/inward/record.url?scp=84969240166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969240166&partnerID=8YFLogxK
U2 - 10.1016/j.cardfail.2016.04.008
DO - 10.1016/j.cardfail.2016.04.008
M3 - Review article
C2 - 27103426
AN - SCOPUS:84969240166
SN - 1071-9164
VL - 22
SP - 449
EP - 458
JO - Journal of cardiac failure
JF - Journal of cardiac failure
IS - 6
ER -